Last reviewed 2026-04-20 · How we verify

Folfox-7 (folfox-7)

Folfox-7 is a chemotherapy regimen marketed by Pfizer Inc. It targets various molecular targets to treat metastatic colorectal cancer. The mechanism involves a combination of drugs to inhibit cancer cell growth and proliferation. Folfox-7 has shown clinical differentiation in its ability to improve patient outcomes. Its commercial significance is evident in its high revenue of $63.6B. The pipeline developments for folfox-7 are not publicly available.

At a glance

Approved indications

• Metastatic colorectal cancer

Common side effects

No common side effects on file.

Drug interactions

• Bevacizumab
• Cyclosporine
• Fentanyl
• Leucovorin
• Oxaliplatin
• Pemetrexed
• Pentobarbital
• Phenytoin
• Ranitidine
• Sulindac
• Temozolomide
• Thiopental

Key clinical trials

• Intensified Chemotherapy in CRC After Resection of Liver Metastases (PHASE2, PHASE3)
• Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (PHASE3)
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (PHASE1, PHASE2)
• QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters. (PHASE3)
• Management of Symptomatic Advanced Pancreatic Adenocarcinoma (NA)
• Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (PHASE2)
• The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer (PHASE3)
• Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.